http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Inhibitoin of Human Malignant Glioma Growth In Vivo by Human Recombinant Plasminogen Kringles 1-3
Park,Chun Kun,Joe,Kyung Keun,Kim,Moon Chan,Joe,Young A,Son,Byung Chul,Jeun,Shin Soo,Yang,Youn Joo,Kang,Joon Ki,Hong,Yong Kil,Lee,Kwan Sung,Lee,Youn Soo,Lee,Hyo Sil,Chung,Soo Ii,Chung,Dong Sup 가톨릭중앙의료원 가톨릭암센터 1999 암심포지움 Vol.- No.2
Human malignant gliomas are highly vascularized and aggressive tumors. Angiogenesis inhibitors have shown to induce regression of a variety of primary and metastatic tumors in vivo. However, their usefulness in treating brain tumors is not wellunderstood. Angiostatin, a multiple kringle (1-4 out of 5) containing fragment of plasminogen, is one of the highly effective natural cryptic angiogenesis inhibitors. In this study, the theraperutic efficacy of a non-glycosylated and small molecular size recombinant kringles 1-3(rPK1-3) was examined in the treatment of brain tumors generated by stereotactic intracerebral implantation of U-87 human glioma cells in nude mice. Mice bearing tumors, post-7 day implant, were treated with rPK1-3(100 mg/kg/day) s.c. for 21 days. The treated animals showed suppressed brain tumor growth by greater than 71.2% along with a 3-fold increase of apoptotic index and suppressed vascularization by 78.9%, without any observable signs of toxicity. Analysis of bFGF and VEGF expression in the tumors of the treated animals using immunohistochemical methods showed near complete absence of growth factors. Our results indicate that a non-glycosylated, small molecular size rPK1-3 is an efficient tumoristatic agent for the treatment of intracranial human glioma wenograft in mice and might provide ew strategies for the treatment of brain tumors.
둥근마 (Dioscorea opposita)와 열대둥근마 (Dioscorea alata)의 관수효과
Chang Ki Son,Jung Hwan Lee,Hyo Hoon Nam,Jung Bae Kwon,Kee Choon Park,Chun Geon Park,Young Sup Ahn 한국약용작물학회 2016 한국약용작물학술대회 발표집 Vol.2016 No.05
Background : Yam absorbs nutrition and water through water absorptive root generated from head of rhizome. Round-shaped yam (RSY, Dioscorea opposita) and tropical round-shaped yam (TRSY, Dioscorea alata)are more sensitive to drought because of shorter head of rhizome and shallower root compared to long yam or short yam. This study was conducted to elucidate the effect of irrigation on RSY and TRSY yam at 205 in Institute of Bioresources Research, GBARES. Methods and Results : Tuber of RSY and TRSY were cut as 40 g, and dust-coating sterilized with lime. Seedlings were grown in heating wire installed seed bed from 25. March to 16. April. Experimental field were fertilized 2,000 kg compost, 34 kg N2, 28 kg P2O5, and 28 kg K2O. All amount of compost and P2O5 treated as basal fertilizer. N2 and K2O treated 14 and 10 kg of basal fertilizer, and 20 and 18 kg of additional fertilizer, respectively. Tillage, installation of drop-watering tapes, and covering black PE film with 60×25 cm spacing holes on 120 cm row were conducted. 20 L per m2 was irrigated 7 days interval except rainy day from middle of May to late of September. RSY had high emergence rate in early stage due to irrigation, while TRSY had no difference. Irrigation was not effective on total number of tuber but number of marketable tuber (over 200 g). Marketable tuber yield of RSY according to irrigation was increased 89% as 1,147 kg per 10 a. And tuber with irrigation was 73 g heavier. Tuber yield and marketable tuber yield of TRSY as affected by irrigation were respectively 2,611 and 1,715 kg per 10 a compared to control, 1,462 and 428 kg. And irrigated tuber was 66 g heavier. Conclusion : TRSY had more effective on irrigation than RSY. Both of yam had significant increased marketable tuber yield due to irrigation. Therefore RSY and TRSY are necessarily irrigated because of those absorptive characteristics, short head of tuber and shallow root.
Ahn, Beung-Chul,Pyo, Kyoung-Ho,Xin, Chun-Feng,Jung, Dongmin,Shim, Hyo Sup,Lee, Chang Young,Park, Seong Yong,Yoon, Hong In,Hong, Min Hee,Cho, Byoung Chul,Kim, Hye Ryun Springer; 1999 2019 Journal of Cancer Research and Clinical Oncology Vol.145 No.6
<P><B>Purpose</B></P><P>Immune checkpoint inhibitors (ICI) have shown marked responses in patients with non-small cell lung cancer (NSCLC) in clinical trials. However, because such trials comprise cohorts selected based on specific criteria, it is unclear if their results represent routine clinical practice.</P><P><B>Methods</B></P><P>We examined 155 patients with advanced NSCLC who were administered either nivolumab or pembrolizumab at Yonsei Cancer Center, Korea between March 2014 and January 2019. Patient characteristics, <I>EGFR</I>/<I>ALK</I> mutation status, metastatic locations, response to ICIs, and adverse events were retrospectively analyzed.</P><P><B>Results</B></P><P>The median age was 64 years and 72.9% of patients were male; former or current smokers constituted 67.1% of the subjects. Adenocarcinoma was predominant (67.7%), and 50.3% of the patients underwent ≥ 2 previous treatments. Twenty-three patients (14.8%) were <I>EGFR</I> mutation- or <I>ALK</I> rearrangement-positive. The objective response rate (ORR) was 23.9% [95% confidence interval (CI) 17.4–31.4%]; the median progression-free survival (PFS) and overall survival (OS) were 3.06 (95% CI 1.893–4.21) and 10.25 (95% CI 5.39–15.11) months, respectively. Multivariate analysis identified ECOG performance status, <I>EGFR</I> mutation/<I>ALK</I> rearrangement status, liver metastasis and PD-L1 proportion as independent predictors of OS. Furthermore, 61.9% of the patients had adverse events of any grade; 38.1% had immune-related adverse events that were associated with PFS and OS on multivariate analysis.</P><P><B>Conclusions</B></P><P>The real-world ORR, PFS, OS, and adverse event profiles were comparable to previous clinical trials despite the patients’ different baseline characteristics. Our findings can aid in establishing effective immunotherapeutic management of NSCLC in routine clinical practice.</P><P><B>Electronic supplementary material</B></P><P>The online version of this article (10.1007/s00432-019-02899-y) contains supplementary material, which is available to authorized users.</P>